Kiniksa Pharmaceuticals International, plc (KNSA) /
The revenue of Kiniksa Pharmaceuticals International, plc over the past 9 years
Chart Kiniksa Pharmaceuticals International, plc: revenue, fiscal 2017–2025 Open the chart →Kiniksa Pharmaceuticals International, plc reported revenue of $677.56M in fiscal 2025, the latest fiscal year on file. In fiscal 2021 it was $38.54M — up 1658% over 4 years. Year over year, revenue rose every year. The largest one-year move was in fiscal 2022: up 471%, from $38.54M to $220.18M.
Year by year
| Fiscal year | Revenue |
|---|---|
| 2025ended Dec 31, 2025 | $677.56M |
| 2024ended Dec 31, 2024 | $423.24M |
| 2023ended Dec 31, 2023 | $270.26M |
| 2022ended Dec 31, 2022 | $220.18M |
| 2021ended Dec 31, 2021 | $38.54M |
| 2020ended Dec 31, 2020 | — |
| 2019ended Dec 31, 2019 | — |
| 2018ended Dec 31, 2018 | — |
| 2017ended Dec 31, 2017 | — |
Fiscal years as Kiniksa Pharmaceuticals International, plc reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Kiniksa Pharmaceuticals International, plc
- The profitability of Kiniksa Pharmaceuticals International, plc
- The cash flow of Kiniksa Pharmaceuticals International, plc
- The debt of Kiniksa Pharmaceuticals International, plc
- All of Kiniksa Pharmaceuticals International, plc's financials, charted
Companies of a similar size
- CAVACAVA Group, Inc.
- WFRDWeatherford International plc
- MSMMSC INDUSTRIAL DIRECT CO., INC.
- KVYOKlaviyo, Inc.
- DOCSDoximity, Inc.
Not investment advice. This page shows what Kiniksa Pharmaceuticals International, plc filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.